Gain Therapeutics Stock Discussion

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure

$Gain Therapeutics (GANX.US)$
shared via @Teddy123 Thanks!!

$Gain Therapeutics (GANX.US)$ Gain slips after early-stage data for Parkinson’s therapy

$Gain Therapeutics (GANX.US)$ LOL shorts won again HAHAHA

$Gain Therapeutics (GANX.US)$ Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease
2 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE

$Gain Therapeutics (GANX.US)$
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease.
The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at a...